Bristol-Myers Squibb's Losing Streak Continues

Bristol-Myers Squibb's stock has ended in the red for the seventh consecutive session, closing at $44.20, a 1.58% decline. The stock has lost over 3% since September 16 and has declined by nearly 21% year-to-date. The company's performance contrasts with the broader market, which has seen a 12.86% rise in the same period.

Bristol-Myers Squibb (BMY) closed the trading session on September 12, 2025, at $44.20, marking a 1.58% decline from the previous session. This is the seventh consecutive session in which the stock has ended in the red. Since September 16, the stock has lost over 3%, and year-to-date, it has declined by nearly 21%. This performance starkly contrasts with the broader market, which has seen a 12.86% rise in the same period Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know^[1].

Analysts and investors are closely monitoring Bristol-Myers Squibb's earnings disclosure, scheduled for October 30, 2025. The company is forecasted to report an EPS of $1.65, representing an 8.33% downward movement from the corresponding quarter of the prior year. Meanwhile, revenue is expected to be $11.77 billion, down 1.03% from the prior-year quarter How To Put $100 In Your Retirement Fund Each Month With Bristol-Myers Squibb Stock^[2].

The stock is currently trading at a Forward P/E ratio of 7.1, indicating a discount compared to the industry's Forward P/E of 20.03. Additionally, the PEG ratio of 2.37 suggests that the company's expected earnings growth rate is taken into account. The Medical - Biomedical and Genetics industry, which includes Bristol-Myers Squibb, has an average PEG ratio of 1.64 Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know^[1].

Bristol-Myers Squibb's recent earnings report for the second quarter of 2025 indicated adjusted EPS of $1.46, missing the consensus estimate of $1.58. However, revenues of $12.30 billion came in above the consensus of $11.31 billion. The company has raised its full-year 2025 revenue guidance from a range of approximately $45.8 billion to $46.8 billion to a range of $46.5 billion to $47.5 billion How To Put $100 In Your Retirement Fund Each Month With Bristol-Myers Squibb Stock^[2].

Investors should also pay attention to any latest changes in analyst estimates for Bristol-Myers Squibb. Upbeat changes in estimates can indicate a favorable outlook on the business health and profitability. The Zacks Rank system, which considers these estimate changes, provides a simple, actionable rating system. Bristol-Myers Squibb currently boasts a Zacks Rank of #3 (Hold) Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know^[1].

References
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know^[1] https://finance.yahoo.com/news/bristol-myers-squibb-bmy-stock-214504863.html
How To Put $100 In Your Retirement Fund Each Month With Bristol-Myers Squibb Stock^[2] https://finance.yahoo.com/news/put-100-retirement-fund-month-120103363.html